Copyright
©The Author(s) 2020.
World J Clin Cases. Dec 26, 2020; 8(24): 6264-6273
Published online Dec 26, 2020. doi: 10.12998/wjcc.v8.i24.6264
Published online Dec 26, 2020. doi: 10.12998/wjcc.v8.i24.6264
Table 6 Univariate and multivariate analysis of factors contributing to hepatitis B virus reactivation
| Univariant analysis | Odds ratio (95%CI) | Multivariate analysis | Odds ratio (95%CI) | |
| Primary disease in digestion and absorption organs | 0.0051 | 2.65 (1.255-5.595) | 0.0095 | 2.523 (1.24-5.67) |
| HBcAb titer | < 0.0001 | 1.263 (1.122-1.439) | 0.0002 | 1.244 (1.10-1.41) |
| HBsAb titer | 0.1580 | 0.999 (0.998-1.001) | ||
| HBsAb negative | 0.2490 | 1.464 (0.789-2.71) |
- Citation: Sugimoto R, Furukawa M, Senju T, Aratake Y, Shimokawa M, Tanaka Y, Inada H, Noguchi T, Lee L, Miki M, Maruyama Y, Hashimoto R, Hisano T. Risk factors for de novo hepatitis B during solid cancer treatment. World J Clin Cases 2020; 8(24): 6264-6273
- URL: https://www.wjgnet.com/2307-8960/full/v8/i24/6264.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i24.6264